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The control of Trypanosoma brucei gambiense hu-
man African trypanosomiasis (HAT) is compromised by 
low sensitivity of the routinely used parasitologic conﬁ  rma-
tion tests. More sensitive alternatives, such as mini-anion 
exchange centrifugation technique (mAECT) or capillary 
tube centrifugation (CTC), are more expensive. We used 
formal decision analysis to assess the cost-effectiveness 
of alternative HAT conﬁ  rmation algorithms in terms of cost 
per life saved. The effectiveness of the standard method, 
a combination of lymph node puncture (LNP), fresh blood 
examination (FBE), and thick blood ﬁ  lm (TBF), was 36.8%; 
the LNP-FBE-CTC-mAECT sequence reached almost 80%. 
The cost per person examined ranged from €1.56 for LNP-
FBE-TBF to €2.99 for LNP-TBF-CTC-mAECT-CATT (card 
agglutination test for trypanosomiasis) titration. LNP-TBF-
CTC-mAECT was the most cost effective in terms of cost 
per life saved. HAT conﬁ  rmation algorithms that incorporate 
concentration techniques are more effective and efﬁ  cient 
than the algorithms that are currently and routinely used by 
several T.b. gambiense control programs.
H
uman African trypanosomiasis (HAT) is a parasitic 
disease that affects 36 countries in sub-Saharan Af-
rica. The most recent World Health Organization (WHO) 
prevalence estimates are 50,000–70,000 cases worldwide, 
based on a total number of 17,500 new HAT cases per year 
worldwide (1). Trypanosoma brucei gambiense HAT con-
trol activities are based principally on the active detection 
of cases by population screening and subsequent treatment 
of infected patients. Because of the relative toxicity of HAT 
drugs, a correct diagnosis is essential before the treatment 
can begin (2). 
The speciﬁ  city of the card agglutination test for try-
panosomiasis (CATT) used in screening is not 100% ac-
curate, so HAT control programs use a variable sequence 
of parasitologic tests as conﬁ  rmation tests. In the Demo-
cratic Republic of Congo (DRC), this sequence, called 
the standard algorithm, comprises lymph node puncture 
(LNP), followed by fresh blood examination (FBE) and 
thick blood ﬁ  lm (TBF). Several authors have reported on 
the low sensitivity levels of HAT conﬁ  rmation tests (3,4). 
Paquet et al. reported that mobile HAT screening teams 
in Uganda detected only 39% of all HAT cases (5). HAT 
cases missed by population screening will later be diag-
nosed by ﬁ  xed health services operating in the same areas 
as the mobile teams, but almost invariably not until the late 
stages of the disease. HAT conﬁ  rmation is more straight-
forward (6). Late-stage detection is problematic because 
it carries a much poorer prognosis for the patient and for-
goes the principal public health objective of HAT control, 
which is a rapid reduction in transmission. Technical so-
lutions to increase the sensitivity of screening algorithms 
do exist. Several concentration tests have been proposed, 
notably the mini-anion exchange centrifugation technique 
(mAECT) (7), capillary tube centrifugation (CTC) (8), and 
the quantitative buffy coat (QBC) (9). A recent study of 
436 case-patients conducted in Kwamouth, DRC, showed 
that 154 had parasitologic-conﬁ  rmed HAT cases. Although 
good sensitivity was reported, and mAECT and CTC were 
relatively simple to implement, it is not economically fea-
sible to use these innovative tools in the ﬁ  eld. 
Other authors have proposed recourse to serology us-
ing higher cut-offs of the CATT test to increase speciﬁ  c-
ity (referred to as CATT titration, in contrast with CATT 
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whole blood, which is the test used in the ﬁ  rst screening 
step) as part of the algorithm for use in screening, or as a 
test to decide whether to treat. The present study is an anal-
ysis of the cost-effectiveness and value for HAT control 
policy of different HAT conﬁ  rmation algorithms, including 
serologic algorithms.
Methods
A decision-analysis model was used to estimate the 
effectiveness and cost-effectiveness of a number of HAT 
screening-treatment algorithms; different HAT conﬁ  rma-
tion test sequences were compared, including concentra-
tion techniques and CATT titration. Decision analysis is a 
method that quantiﬁ  es the value of several alternative op-
tions in a complex choice. This technique requires the con-
struction of a decision tree, which shows detailed options, 
estimation of the node probabilities, and an evaluation of 
the economic or public health consequences of each option 
(M. John, unpub. data) (10,11). A health service perspec-
tive was taken for this analysis, which includes all screen-
ing and treatment costs generated by the choice of HAT 
test algorithms.
Decision Tree
Fourteen HAT control experts were asked to identi-
fy all relevant test sequences that would conﬁ  rm HAT in 
a given person (i.e., positive in the initial screening test, 
CATT). The availability of these tests was an important 
factor in the expert poll. At the time of this study, QBC was 
no longer manufactured, and for this reason, it was not in-
cluded in our analysis. We analyzed 7 algorithms as shown 
in Table 1. All algorithms imply that only parasitologic 
positives will be put on stage-dependent treatment except 
for the fourth group (serologic algorithm), which indicates 
stage-dependent treatment of persons who are negative for 
parasites but positive by CATT titration.
We constructed a decision tree comparing the algo-
rithms mentioned above (Figure 1); the entry point is a 
person who participates in HAT population screening con-
ducted by a mobile team. There are 4 possible outcomes 
for such a person: a true HAT case-patient is treated, a true 
HAT case-patient remains untreated, a non-HAT case-pa-
tient receives HAT treatment, or a non-HAT case-patient 
remains untreated. These 4 outcomes were evaluated in 
terms of lives saved.
Probabilities
Table 2 shows the probabilities used in this decision 
analysis. The baseline values were generated in a study car-
ried out in Kwamouth between February and May 2004 (4) 
or were retrieved from the literature. In the baseline sce-
nario, we assumed HAT prevalence in the community to 
be 1%. This value is a limit used by HAT-control programs 
to distinguish between severe and nonsevere HAT foci. 
A literature search was performed by using the Medline 
database to ﬁ  nd information reported between 1950 and 
2005 to identify baseline values of parameters with a plau-
sible range. A sensitivity analysis was performed to test 
consistency of our conclusions over the range of plausible 
values.
Effectiveness
The effectiveness of each HAT screening-treatment 
algorithm was estimated, taking into account all steps, in-
cluding screening, conﬁ  rmation, and treatment. The results 
were quantiﬁ  ed in terms of the number of lives saved (con-
ﬁ  rmed case, treated, and cured) by each algorithm. HAT 
treatment decision depends on disease staging (20). A di-
agnostic algorithm can theoretically generate 4 different 
outcomes: true positive, false positive, true negative, and 
false negative. 
Effectiveness values were assigned to each of the al-
ternatives. A true HAT case-patient who is treated is equal 
to 0.9 lives saved because the efﬁ  cacy of HAT treatment is 
estimated at 90%, according to data from the Programme 
National de Lutte contre la Trypanosomiase Humaine Af-
ricaine (PNLTHA) between 1996 and 2002. For a few per-
sons, treatment of non-HAT case-patients with toxic drugs 
will lead to iatrogenic death. Therefore, an effectiveness 
value was assigned to this endpoint of –0.001 lives saved 
Table 1. Screening algorithms for human African trypanosomiasis* 
Label Algorithm Abbreviation
Algorithm 1 or standard  Lymph node puncture, fresh blood examination, and thick blood film  LNP-FBE-TBF 
Algorithm 2  Lymph node puncture and capillary tube centrifugation  LNP-CTC
Algorithm 3  Lymph node puncture, CATT titration, capillary tube centrifugation, 
and mini-anion exchange centrifugation technique 
LNP-CATT titration-CTC-mAECT 
Algorithm 4  Lymph node puncture, capillary tube centrifugation, and mini-anion 
exchange technique 
LNP-CTC-mAECT
Algorithm 5  Lymph node puncture, thick blood film, capillary tube centrifugation, 
and mini-anion exchange technique 
LNP-TBF-CTC-mAECT 
Algorithm 6  Lymph node puncture, capillary tube centrifugation, and CATT 
titration
LNP-CTC-CATT titration 
Algorithm 7  Lymph node puncture, thick blood film, capillary tube centrifugation, 
mini-anion exchange technique, and CATT titration 
LNP-TBF-CTC-mAECT 
-CATT titration 
*CATT, card agglutination test for trypanosomiasis; CATT titration, CATT titration at end-titer 8. 
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for ﬁ  rst-stage drugs and –0.020 lives saved for second-
stage drugs. A non-HAT case-patient and a true HAT case-
patient who was untreated were each assigned an effective-
ness value of 0 lives saved.  Effectiveness was expressed 
as the percentage of HAT deaths averted by a strategy. To 
obtain the actual number of lives saved by the strategy, this 
value must be multiplied by HAT prevalence.
Costs
While assessing the different algorithms, we distin-
guished between 3 steps in the process: 1) screening, 2) 
conﬁ  rmation, and 3) treatment. Using the ingredient ap-
proach, we estimated the cost of screening by the mobile 
team for HAT on the basis of observations made in 2003. 
A detailed overview of cost items is given in Table 3. The 
cost of the screening step includes all equipment required 
to set up a mobile team: vehicles, depreciation, operating 
costs, and CATT reagents. 
For the second step (HAT conﬁ  rmation), each conﬁ  r-
mation test was assessed in terms of resources consumed, 
equipment depreciation, and time taken by a mobile team 
to realize each test. Data on costs and time were collected 
during a validation study conducted in Kwamouth in 2004 
(4). The time for each diagnostic test was estimated by us-
ing a stopwatch for a sample of 50 procedures, and the re-
sults were measured in terms of minutes elapsed. The cost 
of LNP has been estimated as €0.19, FBE at €0.21, TBF at 
€0.54, CTC at €0.76, and mAECT at €2.82 (4). 
The third step, treatment, includes the cost of hospi-
talization care (ﬁ  xed cost) as well as the cost of drugs and 
medical supplies. Preferential drug prices that are current-
ly applicable were used in the calculations (pentamidine 
€1.54/vial, melarsoprol €5.3/vial), and the number of doses 
was 8 for pentamidine and 9 for melarsoprol. We assumed 
Table 2. Probabilities used in baseline scenario and plausible range* 
Characteristic Baseline value, % Reference Plausible range, % Reference 




LNP sensitivity  18.8  (12) 18.8–58.6 (3,4)
LNP specificity  100.0 By convention  NA
FBE sensitivity  3.9 (4) 3.9–22.4 (3,4)
FBE specificity  100.0 By convention  NA
TBF sensitivity  27.3 (4) 27.3–34.5 (3,4)
TBF specificity  100.0 By convention  NA
CTC sensitivity  56.5 (4) 29.0–73.0 (3,7)
CTC specificity  100.0 By convention  NA
mAECT sensitivity  75.3 (4) 43.0–88.0 (3,7)
mAECT specificity  100.0 By convention  NA
CATT whole blood sensitivity  90.4 (13 68.8–99.2 (13–16); M. John, unpub. data 
CATT whole blood specificity  96.5 (13) 83.5–98.4 (21,23,24)
CATT titration sensitivity†  78.8  (4) 78.8–100.0 In absence of data in literature, we 
considered the maximum of 100%
CATT titration specificity†  59.0 (4) 59.0–100.0 In absence of data in literature, we 
considered the maximum of 100%
Pentamidine efficacy  98.0 ‡ 98.0–99.0   (17)
Melarsoprol efficacy  90.0 ‡ 70.0–96.3 (17,18)   
Latrogenic mortality of 
pentamidine
0.1 ‡ 0.1–0.7   (17)
Latrogenic mortality of 
melarsoprol
2.0 2.0–7.0 (17–19)
*HAT, human African trypanosomiasis; PNLTHA, Programme National de lutte contre la Trypanosomiase Humaine Africaine; LNP, lymph node puncture; 
NA, not applicable; FBE, fresh blood examination; TBF, thick blood film; CTC, capillary tube centrifugation technique; mAECT, mini-anion exchange 
centrifugation technique; CATT, card agglutination test for trypanosomiasis. 
†Conditional values to CATT whole blood positive. The plausible range included the value at different end-titers (4, 16, 32). 
‡Data extracted from PNLTHA/RDC annual report 1999. 
Table 3. Annual cost of the operations of a mobile team for 
human African trypanosomiasis (HAT) active case finding, 
Democratic Republic of Congo, 2003 
Input category  Annual cost, €*  % Total cost 
Capital
Vehicles 5,125.00 11
Medical and lab equipment 2,760.00 6
Training 671.66 1




Medical and lab supply   14,798.52 32
Essential drugs, not for HAT   2,100.00 4




Other operating input   300.00 1
Subtotal 36,760.88 79
Total 46,734.29 100
*US $1 = €0.86, May 2003. 
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that 50% of case-patients were in stage 1 (needing pentami-
dine) and 50% were in stage 2 (needing melarsoprol). 
Analysis
The efﬁ  ciency of each algorithm was evaluated on the 
basis of the cost-effectiveness ratio expressed in terms of €/
life saved. This ratio was obtained by dividing the cost (in 
€) per person examined for each algorithm by the strategy’s 
effectiveness (in % HAT deaths averted per person exam-
ined), multiplied by HAT prevalence. 
We used the following equations: 
€/life saved = (€/person examined) / [(HAT prevalence) 
× (sensitivity of test sequence) × (effectiveness of HAT 
treatment) – (1–HAT prevalence) × (1–speciﬁ  city of test 
sequence) × (probability of iatrogenic death)]
Cost per person examined = [(total annual operating costs 
of a mobile team) / (number of persons screened per year)] 
+ [cost of conﬁ  rmatory testi × probability conﬁ  rmatory 
testi] + [cost of treatmentk × probability treatment true 
positive)] + [cost of treatmentk × probability treatment 
false positive] 
where cost of conﬁ  rmatory  testi = cost of material + 
execution time + depreciation of equipment; i = LNP, FBE, 
TBF, CTC, mAECT, or CATT titration; cost of treatmentk 
= cost of hospitalization care + cost of drugs + cost of 
medical supplies; k = therapy of a true ﬁ  rst-stage case, a 
true second-stage case, or a false-positive person; and 
probability conﬁ  rmatory testi = the probability of executing 
conﬁ  rmatory test in position i in the test sequence of the 
evaluated algorithm. This probability was derived from the 
decision tree as follows:
[prevalence × sensitivityCATT whole blood × 
(1–sensitivityconﬁ  rmatory test 1) × ...× (1–sensitivityconﬁ  rmatory test i –1)] 
+ [(1 – prevalence) × (1 – speciﬁ  cityCATT whole blood)]
Probability of treatment of a true-positive person was 
calculated per stage z (1,2) as follows:
prevalence × proportion of casesstage z × 
sensitivityCATT whole blood × sensitivityconﬁ  rmatory test 1 × ... × 
sensitivityconﬁ  rmatory test i–1 × sensitivityconﬁ  rmatory test i 
Probability of treatment of a false-positive person was 
generally deﬁ  ned as:
(1 – prevalence) × (1 – speciﬁ  cityCATT whole blood) × 
(1 – speciﬁ  cityconﬁ  rmatory test 1) × ... × 
(1 – speciﬁ  cityconﬁ  rmatory test i–1) × (1 – speciﬁ  cityconﬁ  rmatory test i )
However, for algorithms including CATT titration 
without subsequent conﬁ  rmation, the probability of treat-
ment of a false-positive person was deﬁ  ned as:
(1 – prevalence) × (1 – speciﬁ  cityCATT whole blood) × 
(1 – speciﬁ  cityconﬁ  rmatory test 1) × ... × 
(1 – speciﬁ  cityconﬁ  rmatory test i–1) × (1 – speciﬁ  cityconﬁ  rmatory test i ) 
+ (1 – speciﬁ  cityCATT whole blood) × (1 –  speciﬁ  cityCATT titration).
Effectiveness of HAT treatment was deﬁ  ned for true 
cases as: 
[(proportion of stage 1 cases) × (efﬁ  cacy pentamidine)] + 
[(proportion of stage 2 cases) × (efﬁ  cacy melarsoprol)]
Finally, we calculated the incremental cost-effective-
ness ratio (ICER) of saving 1 additional HAT patient by 
comparing each alternative algorithm to the strategy im-
mediately above it after ranking the order of effectiveness. 
The ICER was calculated as incremental cost / (incremen-
tal effectiveness × HAT prevalence).
HAT prevalence, sensitivity, and speciﬁ  city of differ-
ent tests were the subject of a sensitivity analysis. A series 
of 1-way sensitivity analyses were conducted to examine 
Table 4. Cost, incremental cost, effectiveness, incremental effectiveness, cost effectiveness, and incremental cost effectiveness ratio 












LNP-FBE-TBF 36.80 1.56 423.91
LNP-CTC  55.00 18.20 1.74 0.18 316.36 98.90
LNP-CATT titration-CTC-mAECT  64.50 9.50 1.96 0.22 303.88 231.58
LNP-CTC-mAECT 77.60 13.10 2.06 0.10 265.46 76.34
LNP-CTC-CATT titration  77.80 0.20 2.82 0.76 362.47 Dominated
LNP-TBF-CTC-mAECT  79.60 2.00 2.1 0.04 263.82 200.00
LNP-TBF-CTC-mAECT-CATT titration  83.00 3.40 2.99 0.89 360.24 2617.65
*HAT prevalence 1%. HAT, human African trypanosomiasis; LNP, lymph node puncture; FBE, fresh blood examination; TBF, thick blood film; CTC, 
capillary tube centrifugation; CATT, card agglutination test for trypanosomiasis; CATT titration, CATT titration at end-titer 8; mAECT, mini-anion-exchange 
centrifugation technique. Cost/effectiveness ratio calculated as cost / (effectiveness × prevalence). Differences due to rounding in table. US $1 = Euro 
0.79, Feb 2004. 
†% HAT deaths averted. 
‡Cost and effectiveness calculated incremental to next least effective nondominated algorithm after ranking all algorithms by effectiveness. 
§Cost effectiveness per life saved. 
¶Incremental cost effectiveness ratio calculated as incremental cost / (incremental effectiveness × HAT prevalence). Differences due to rounding in table. 
All incremental changes expressed in comparison with LNP-FBE-TBF algorithm. 
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the effect of changes in those parameters over the plausible 
range mentioned in Table 2 on the efﬁ  ciency ranking of 
strategies. DATA Pro 2004 software (TreeAge, William-
stown, MA, USA) was used for this analysis. 
Results
We estimated the cost of population screening for HAT 
conducted by a mobile team in 2003 (excluding the cost 
related to conﬁ  rmation and treatment) at €1.17/per person 
examined (Table 4). The treatment cost was estimated at 
€51.32/person treated with pentamidine and €129.92/per-
son treated with melarsoprol.
Table 4 shows the cost and effectiveness per person ex-
amined for the complete screening-treatment process. Fur-
thermore, it presents the incremental cost, the incremental 
effectiveness, and the incremental cost-effectiveness ratio of 
each algorithm compared with the next least effective. Table 
4 shows that algorithm 5 is the most cost effective algorithm 
(€264.02/life saved), with algorithm 4 a close second-best 
option (€265.98/life saved). Although the cost per person 
examined for the 2 algorithms does not differ substantially, 
algorithm 5 is slightly more efﬁ  cacious, saving 79.60% of 
avoidable deaths versus 77.60% for algorithm 4. 
The standard algorithm (algorithm 1) had an effective-
ness of 36.80% with a €/person examined of €1.56 and an 
efﬁ  ciency of €424.94/life saved. From column 7 in Table 4, 
the incremental cost-effectiveness ratio to save 1 additional 
life ranged between €76.34 and €200/life saved for the con-
centration technique algorithms and €2,617.65/life saved if 
the decision to treat was based on serologic evidence. Al-
gorithm 6 was dominated by algorithm 5 because algorithm 
6 costs more and is less effective.
The sensitivity analysis showed that our conclusion re-
mained robust to variation over the range of uncertainty in 
all parameters included in the model (Figure 2). Changes in 
the speciﬁ  city of CATT and CATT titration, cost of pent-
amidine, and HAT prevalence decreased the difference in 
the cost-effectiveness ratio with the next most efﬁ  cient al-
gorithm. Figure 3 shows the variation of the cost-effective-
ness ratio in function of the prevalence.
Discussion
Current observations suggest that parasitologic con-
ﬁ  rmation tests of inadequate sensitivity lead to suboptimal 
effectiveness of HAT active case-ﬁ   nding programs (4). 
Our analysis shows that concentration techniques, and to a 
lesser extent, serologic tests can substantially improve the 
efﬁ  ciency of HAT conﬁ  rmation algorithms. The currently 
used algorithm (standard algorithm) was the least cost ef-
fective of all those compared, mainly because its sensitiv-
ity is so low. Low effectiveness of the standard algorithm 
was also reported by Paquet et al. (5), Pépin et al. (6), and 
recently by Robays et al. (13) who put it respectively at 
39.5%, 20–30%, and 50%. The greater effectiveness of 
concentration techniques (currently €2.82/test for mAECT) 
more than compensates for the higher cost. Serologic al-
gorithms were not more cost effective than the algorithms 
that included concentration techniques, but the difference 
in efﬁ  ciency decreased at a higher prevalence (Figure 3). 
Algorithms combining CATT titration with subsequent 
conﬁ  rmation by concentration techniques were not com-
petitive in this analysis; efﬁ  ciency always remained lower 
than that of algorithms based exclusively on concentration 
techniques. This is due to the loss of patients caused by the 
suboptimal sensitivity of CATT titration. 
Figure 2. Sensitivity analysis of cost effectiveness (€/life 
saved) according to variation in prevalence of human African 
trypanosomiasis (HAT). CTC, capillary tube centrifugation; 
mAECT, mini-anion-exchange centrifugation technique; CATT, card 
agglutination test for trypanosomiasis.
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Figure 1. Decision tree comparing algorithms used to analyze human 
African trypanosomiasis (HAT). LNP, lymph node puncture; FBE, 
fresh blood examination; TBF, thick blood ﬁ  lm; CTC, capillary tube 
centrifugation; CATT, card agglutination test for trypanosomiasis; 
CATT titration, CATT titration at end-titer 8; mAECT, mini-anion-
exchange centrifugation technique.Algorithms for Human African Trypanosomiasis
Our study could shed some light on the controversial 
issue of treating for HAT on the basis of serologic evidence. 
In a similar discussion in the ﬁ  eld of kala-azar case manage-
ment, Boelaert et al. (14) argued that a serologic algorithm 
was more cost effective, and therefore a better choice, than 
a parasitologic algorithm with poor sensitivity. 
In this study, we also ﬁ  nd that treating patients sus-
pected by serologic tests to have HAT is a better option 
than using the current algorithm without concentration 
techniques. This may be a valuable strategy when intro-
duction of mAECT or CTC is not yet feasible. A limita-
tion of the study is that the speciﬁ  city values of CATT and 
CATT dilution are based on data from 1 region and might 
be underestimated given ﬁ  ndings from routine data from 
the national program (4). However, this regional variation 
remains poorly documented, and better estimations of the 
speciﬁ  city of CATT in different regions are needed. The 
use of CATT titration has primarily been evaluated in the 
group of CATT whole blood–positive persons who were 
negative for parasites. Chappuis et al. (15), Simarro et al. 
(16), Van Nieuwenhove and Declercq (17), Frézil et al. 
(18), and Bruneel et al. (19) evaluated the strategy of treat-
ing persons who had positive serologic test results (indirect 
immunoﬂ  uorescent antibody test or CATT) and who were 
negative for parasites and found this strategy more effec-
tive than that based on parasitologic conﬁ  rmation. 
Our model did not give different weights to iatrogenic 
deaths of noninfected persons compared with infected per-
sons. This point should be carefully considered because the 
serologic algorithm will expose some noninfected persons 
to toxic drugs. However, as no treatment with second-stage 
HAT drugs will be given unless a lumbar puncture and 
parasitologic conﬁ  rmation in cerebrospinal ﬂ  uid are ob-
tained, the exposure of noninfected persons to the highly 
toxic second-stage HAT drugs will be minimal, even under 
a serologic algorithm.
Our decision analysis is based on a model that depends 
on certain assumptions made for the purpose of simpliﬁ  -
cation. An important assumption is that a true HAT case 
missed by the mobile teams will eventually die; in practice, 
if treatment is sought, this patient’s condition might be di-
agnosed and cured, or alternatively, HAT could be detected 
later by the mobile team on a second visit. We examined 
whether this assumption would change our conclusions by 
hypothesizing that 40% of such HAT case-patients would 
be detected and treated at a later stage. In this scenario, the 
differences between algorithms in terms of cost-effective-
ness are reduced without altering the relative order (data 
not shown). 
Second, conﬁ  rmation tests in the sequence were used 
as if they were independent, but in reality, this is unlikely. 
For example, mAECT sensitivity could be different in a 
group of TBF-positive persons compared to a group of 
TBF-negative persons. We have examined the effect of 
this conditional relationship on the ﬁ  ndings of our study by 
means of sensitivity analysis (data not shown). Once again, 
these variations did not affect the ranking of the results. 
The cost of the mobile team per person screened was 
estimated on the basis of 40,000 examinations per year 
(20). Even if the program could screen 60,000 persons per 
mobile team per year, it would not change the rank order of 
efﬁ  ciency. Finally, better conﬁ  rmation algorithms for HAT 
may also have a beneﬁ  cial effect on transmission because 
there will be fewer undetected cases to spread the disease 
in the community. If such an effect is considered, it might 
favor the efﬁ  ciency of treatment based on serologic mark-
ers, which may lead to a faster reduction of the human res-
ervoir similar to the chemoprophylaxis campaigns of the 
1950s. Unfortunately, no sufﬁ  ciently validated models for 
T. b. gambiense sleeping sickness transmission allow for 
the estimation of this potential beneﬁ  t at population level. 
Our analysis disregarded this potential future beneﬁ  t. 
A policy change in HAT population screening seems 
deﬁ  nitely needed, and there is ample scope for improv-
ing the sensitivity of the conﬁ  rmation stage. Introducing 
algorithm 5 has an incremental cost-effectiveness ratio of 
€200.00/(additional) life saved. This ratio represents the 
cost to HAT control programs of shifting to algorithm 5 
(the most cost effective) to save an additional life. This 
choice seems very rational. The incremental cost-effective-
ness ratio was €76.34 if HAT control programs chose algo-
rithm 4. TBF is a lengthy procedure, and dropping it from 
the sequence has logistic and organizational advantages. 
Our calculations were based on an estimate of 47 minutes 
of staff time required for TBF, obtained in a previous study 
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Figure 3. Variations in cost effectiveness ratios as a function of 
prevalence of human African trypanosomiasis (HAT). LNP, lymph 
node puncture; FBE, fresh blood examination; TBF, thick blood 
ﬁ   lm; CTC, capillary tube centrifugation; mAECT, mini-anion-
exchange centrifugation technique; CATT, card agglutination test 
for trypanosomiasis; CATT titration, CATT titration at end-titer 8.GLOBAL POVERTY  RESEARCH
(4). However, because labor costs are so low in the DRC 
and TBF does not require expensive reagents or equipment, 
it remains a very affordable test whenever there are no time 
constraints for staff.
In conclusion, the standard HAT screening algorithm 
has low sensitivity and is inefﬁ  cient. Inclusion of concen-
tration techniques in HAT screening algorithms can be 
recommended as cost effective alternatives. The use of se-
rologic algorithms should be studied further before being 
recommended for HAT population screening.
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